Roche (RHHBY) announced the results from a Phase 3 clinical trial, OAK. The results showed RHHBY's TECENTRIQ (atezolizumab) statistically significantly improved overall survival (OS) compared to docetaxel chemotherapy in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemo. The data will be presented at an upcoming medical conference.